Beyond Air (XAIR) 주식 개요
Beyond Air, Inc.는 상용화 단계에 있는 의료기기 및 바이오의약품 기업으로 운영되고 있습니다. 자세히 보기
XAIR Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Beyond Air, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$3.09 |
| 52주 최고가 | US$55.60 |
| 52주 최저가 | US$3.06 |
| 베타 | 0.13 |
| 1개월 변동 | -40.69% |
| 3개월 변동 | -57.08% |
| 1년 변동 | -93.07% |
| 3년 변동 | -99.71% |
| 5년 변동 | -99.90% |
| IPO 이후 변동 | -99.88% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Sep 08
XAIR: Reverse Split And Gen 2 Approval Could Unlock Recurring Revenue Upside
Analysts recently reset their fair value estimate for Beyond Air from $280 to $20, citing new coverage that highlights the potential for LungFit driven recurring revenue and an updated P/E based framework tied to anticipated Gen 2 device approval and a refreshed management strategy. Analyst Commentary Recent Street research on Beyond Air focuses heavily on the potential of the LungFit platform and how it could influence valuation, growth in recurring revenue, and execution risk around upcoming product milestones.내러티브 업데이트 • Aug 11
XAIR: Reverse Stock Split Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Beyond Air from $160 to $280, citing updated assumptions around the discount rate, revenue growth, and profit margin in their pricing models. What’s in the News for Beyond Air Beyond Air plans a 1-for-20 reverse stock split, with the board approving the ratio on June 18, 2026, after stockholders authorized a potential range between 1-for-2 and 1-for-20 at a special meeting.Recent updates
내러티브 업데이트 • Sep 08
XAIR: Reverse Split And Gen 2 Approval Could Unlock Recurring Revenue Upside
Analysts recently reset their fair value estimate for Beyond Air from $280 to $20, citing new coverage that highlights the potential for LungFit driven recurring revenue and an updated P/E based framework tied to anticipated Gen 2 device approval and a refreshed management strategy. Analyst Commentary Recent Street research on Beyond Air focuses heavily on the potential of the LungFit platform and how it could influence valuation, growth in recurring revenue, and execution risk around upcoming product milestones.내러티브 업데이트 • Aug 11
XAIR: Reverse Stock Split Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Beyond Air from $160 to $280, citing updated assumptions around the discount rate, revenue growth, and profit margin in their pricing models. What’s in the News for Beyond Air Beyond Air plans a 1-for-20 reverse stock split, with the board approving the ratio on June 18, 2026, after stockholders authorized a potential range between 1-for-2 and 1-for-20 at a special meeting.내러티브 업데이트 • Jul 27
XAIR: Reverse Stock Split And Listing Compliance Will Support Future Upside
Analysts have reset their fair value estimate for Beyond Air to $160.00, reflecting updated assumptions for revenue growth, profit margins and the removal of the future P/E input in their valuation framework. What’s in the News for Beyond Air Beyond Air plans either a 1-for-20 reverse stock split or a significant stock dividend, scheduled for July 13, 2026, according to a key corporate actions update.
내러티브 업데이트 • Jul 13
XAIR: Reverse Split Plan Will Set Stage For Future Upside
Analysts have adjusted their price target for Beyond Air from $14.00 to $280.00, citing updated assumptions on discount rate, revenue growth, profit margin, and future P/E used in their valuation analysis. What’s in the News for Beyond Air Beyond Air plans a 1-for-20 reverse stock split or significant stock dividend, expected to take effect on July 13, 2026, according to company disclosures.내러티브 업데이트 • Jun 17
XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future Upside
Analysts have kept their Beyond Air price target broadly stable, with only a minor adjustment that reflects small tweaks to projected profit margins and future P/E assumptions rather than a change in the core outlook. What’s in the News for Beyond Air Beyond Air scheduled a Special Shareholders Meeting for June 18, 2026, to vote on a proposal that would allow the Board to carry out a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-20, at any time up to one year after the meeting, subject to shareholder approval.내러티브 업데이트 • Jun 03
XAIR: Future Hospital Access Agreement Will Support Long Term Upside Potential
Analysts now see fair value for Beyond Air at $8.00, down from $8.67, reflecting a slightly higher discount rate and marginally softer assumptions for revenue growth, profit margin, and future P/E multiples. What's in the News Beyond Air scheduled a special shareholder meeting for June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, New York, to vote on key corporate matters.
내러티브 업데이트 • May 06
XAIR: Later FDA Decision Will Still Drive Key Future Inflection
Narrative Update Analysts have cut their price target on Beyond Air from $6 to $2, citing lower sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system, which they still view as central to its future revenue and profitability potential. Analyst Commentary Bearish analysts have reacted to the fiscal Q3 update by cutting their price target on Beyond Air to $2 from $6, highlighting what they see as a tougher setup for both growth and valuation in the near term.내러티브 업데이트 • Apr 21
XAIR: Later Regulatory Decision Will Still Support Long Term Upside Potential
Analysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.내러티브 업데이트 • Apr 07
XAIR: Later FDA Decision Will Still Unlock Key Future Inflection
Narrative Update The analyst consensus price target for Beyond Air has shifted to $2, down from $6, as analysts point to reduced near term sales assumptions and a later FDA decision timeline for the second generation LungFit PH system, while still highlighting its potential importance for future revenue growth and profitability. Analyst Commentary Recent Street research reflects a more cautious stance on Beyond Air, with bearish analysts recalibrating expectations around both timing and scale of potential revenue from the second generation LungFit PH system.내러티브 업데이트 • Mar 24
XAIR: Extended FDA Timeline Will Still Set Up Key Future Inflection
Analysts have cut their price target for Beyond Air to $2 from $6, citing revised sales timelines, with FDA approval for the second generation LungFit PH system now expected at the end of 2026, while still viewing that potential commercialization as central to future revenue growth and profitability. Analyst Commentary Recent price target revisions highlight a clear divide between long term optimism around LungFit PH and shorter term caution around execution and timing.내러티브 업데이트 • Mar 10
XAIR: Future Regulatory Milestone And Capital Raise Will Underpin Potential Upside
Analysts have cut their price target on Beyond Air to $2 from $6, citing updated sales estimates and a later expected FDA decision for the second generation LungFit PH system as key drivers of their revised outlook. Analyst Commentary Bearish analysts are signaling a more cautious stance on Beyond Air, with the latest research move cutting the price target to $2 from $6 and explicitly tying that change to revised expectations around the LungFit PH opportunity and timing.내러티브 업데이트 • Feb 23
XAIR: Later FDA Decision Will Still Support Long Term Upside Potential
Analysts have cut their average price target for Beyond Air from about $12.33 to $8.67, reflecting updated expectations for slower revenue growth, a higher discount rate, and a higher future P/E multiple as they factor in revised sales estimates tied to the later FDA decision timing for the second generation LungFit PH system. Analyst Commentary Bullish Takeaways Bullish analysts still frame the second generation LungFit PH system as a central driver for Beyond Air's long term revenue profile, pointing to commercialization of this product as a potential turning point for the business once regulatory milestones are met.내러티브 업데이트 • Feb 09
XAIR: Bullish Coverage And New Capital Raise Will Support Future Upside
Analysts now see Beyond Air's fair value holding at $6.00 per share, with a slightly higher discount rate and modestly adjusted revenue growth, profit margin, and future P/E assumptions following fresh bullish coverage that supports a constructive long term thesis on the stock. Analyst Commentary Recent coverage frames Beyond Air as a higher risk, higher reward idea, with the current fair value estimate of US$6.00 per share sitting against a backdrop of both optimism and clear caution.내러티브 업데이트 • Jan 25
XAIR: Expanded Distribution And Fresh Capital Will Support Future Upside
Analysts have kept their fair value target for Beyond Air steady at US$6.00, while adjusting their models to reflect updated assumptions on discount rate, revenue growth, profit margin and future P/E following recent bullish Street research coverage. Analyst Commentary While the latest Street coverage has been supportive, some bearish analysts continue to flag risks that they believe are not fully captured in the current US$6.00 fair value estimate.내러티브 업데이트 • Jan 11
XAIR: Expanded Global Distribution And Recent Financing Will Support Future Upside
Analysts have revised their price target for Beyond Air to US$6.00, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E multiples, which leaves the fair value estimate unchanged at US$6.00. What's in the News Beyond Air updated its earnings guidance for the fiscal year ending March 31, 2026, with revenue now guided to a range of US$8 million to US$10 million (Corporate guidance).내러티브 업데이트 • Dec 26
XAIR: Expanded Global Distribution And New Financing Will Support Upside Potential
Analysts have modestly raised their price target on Beyond Air to reflect a slightly higher long term growth outlook and valuation multiple, while incorporating a more conservative discount rate and largely unchanged profit margin assumptions. What's in the News Signed multiple new international distribution agreements for LungFit PH across Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing total coverage to 39 countries and over three billion people (Key Developments).내러티브 업데이트 • Dec 12
XAIR: Stronger Revenue Outlook And Financing Will Support Future Upside Potential
Analysts have raised their price target on Beyond Air to 6.00 dollars from 5.00 dollars, citing slightly stronger expected revenue growth, modestly improved profit margins, and a higher anticipated future price to earnings multiple despite a higher discount rate. What's in the News Chief Financial Officer Doug Larson has resigned to pursue another opportunity and will remain in his role until December 5, 2025.내러티브 업데이트 • Nov 01
XAIR: Global Network Expansion Will Drive Long-Term Market Presence
Analysts have modestly maintained their price target for Beyond Air at $12.33 per share. They cite steady expectations around revenue growth and profit margins, even though there have been minor adjustments to other financial assumptions.내러티브 업데이트 • Oct 18
Global Expansion And Next-Generation Respiratory Care Will Transform Markets
Analysts have raised their price target for Beyond Air from $11.20 to $12.33, reflecting improved revenue growth expectations and a notable increase in projected profit margins. What's in the News The global distribution network for LungFit PH has been expanded, with new agreements in Japan, South Korea, Costa Rica, Guatemala, and El Salvador.내러티브 업데이트 • Sep 04
Global Expansion And Next-Generation Respiratory Care Will Transform Markets
With minimal changes in both the discount rate and future P/E, Beyond Air’s consensus analyst price target remained effectively unchanged at $11.20. What's in the News Expanded global LungFit PH distribution network to 34 countries, including new agreements in Japan (with AMCO), South Korea, Costa Rica, Guatemala, and El Salvador.
새로운 내러티브 • Apr 14
The Next-Generation LungFit PH System Will Open New Markets
International revenue could significantly impact growth due to CE Mark approval and distribution partnerships, especially in the EU.주주 수익률
| XAIR | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | -3.4% | 1.6% | -0.2% |
| 1Y | -93.1% | -16.3% | 11.9% |
수익률 대 산업: XAIR은 지난 1년 동안 -16.3%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: XAIR은 지난 1년 동안 11.9%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| XAIR volatility | |
|---|---|
| XAIR Average Weekly Movement | 16.4% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: XAIR의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: XAIR의 주간 변동성은 지난 1년간 26%에서 16%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2011 | 54 | Bob Goodman | www.beyondair.net |
Beyond Air, Inc.는 상용화 단계에 있는 의료기기 및 바이오의약품 기업으로, Beyond Air, Beyond Cancer, NeuroNos 사업부로 운영되고 있습니다. 이 회사는 신생아 지속성 폐고혈압 치료를 위한 ‘Lungfit PH’를 제공하고 있습니다. 또한 입원 환자의 코로나19 및 세기관지염을 포함한 지역사회 획득성 바이러스성 폐렴과 같은 바이러스성 폐 감염 치료를 위한 ‘LungFit PRO’와 비결핵성 마이코박테리아(NTM) 치료를 위한 ‘LungFit GO’를 개발 중입니다.
Beyond Air, Inc. 기초 지표 요약
| XAIR 기초 통계 | |
|---|---|
| 시가총액 | US$2.95m |
| 순이익 (TTM) | -US$33.49m |
| 매출 (TTM) | US$7.69m |
0.4x
주가매출비율(P/S)-0.1x
주가수익비율(P/E)XAIR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| XAIR 손익계산서 (TTM) | |
|---|---|
| 매출 | US$7.69m |
| 매출원가 | US$7.37m |
| 총이익 | US$321.00k |
| 기타 비용 | US$33.81m |
| 순이익 | -US$33.49m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -34.97 |
| 총이익률 | 4.18% |
| 순이익률 | -435.71% |
| 부채/자본 비율 | 788.9% |
XAIR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/18 21:31 |
| 종가 | 2026/09/18 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Beyond Air, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |
| Justin Walsh | JonesTrading Institutional Services, LLC |